Accueil
Détail de l'auteur
Documents disponibles écrits par cet auteur (17)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Article : Périodique
M. ALAVI ; J. GREBELY ; M. MICALLEF ; A. J. DUNLOP ; A. C. BALCOMB ; C. A. DAY ; C. TRELOAR ; N. BATH ; P. S. HABER ; G. J. DORE |BACKGROUND: Access to hepatitis C virus (HCV) treatment remains extremely limited among people who inject drugs (PWID). HCV assessment and treatment was evaluated through an innovative model for the provision of HCV care among PWID with chronic [...]![Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs [Commentary]](https://bdoc.ofdt.fr/img_cache/d1ffcba1a67f9fdc5d72961dfe2d198d.png)
Article : Périodique
S. LARNEY ; J. GREBELY ; M. HICKMAN ; D. DE ANGELIS ; G. J. DORE ; L. DEGENHARDT |There is considerable interest in determining the impact that increased uptake of treatment for hepatitis C virus (HCV) infection will have on the burden of HCV among people who inject drugs (PWID). An understanding of the size of the population[...]
Article : Périodique
J. GREBELY ; G. J. DORE ; S. MORIN ; J. K. ROCKSTROH ; M. B. KLEIN |INTRODUCTION: Globally, there is a considerable burden of HCV and HIV infections among people who inject drugs (PWID) and transmission of both infections continues. Needle and syringe programme (NSP) and opioid substitution therapy (OST) coverag[...]
Article : Périodique
J. A. KWON ; J. ANDERSON ; C. C. KERR ; H. H. THEIN ; L. ZHANG ; J. IVERSEN ; G. J. DORE ; J. M. KALDOR ; M. G. LAW ; L. MAHER ; D. P. WILSON |OBJECTIVE: To evaluate the impact and cost-effectiveness of needle-syringe programs (NSPs) with respect to HIV and hepatitis C virus (HCV) infections among Australian injecting drug users (IDUs). DESIGN/METHODS: A health economic analysis was [...]
Article : Périodique
S. LARNEY ; M. HICKMAN ; R. GUY ; J. GREBELY ; G. J. DORE ; R. T. GRAY ; C. A. DAY ; J. KIMBER ; L. DEGENHARDT |Background: Injecting drug use is associated with considerable morbidity and mortality. Estimates of the size of the population of people who inject drugs are critical to inform service planning and estimate disease burden due to injecting drug [...]Article : Périodique
Article : Périodique
J. GREBELY ; S. LARNEY ; A. PEACOCK ; S. COLLEDGE ; J. LEUNG ; M. HICKMAN ; P. VICKERMAN ; S. BLACH ; E. B. CUNNINGHAM ; K. DUMCHEV ; M. LYNSKEY ; J. STONE ; A. TRICKEY ; H. RAZAVI ; R. P. MATTICK ; M. FARRELL ; G. J. DORE ; L. DEGENHARDT |BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with[...]
Article : Périodique
ENGLISH : While harm reduction advocates, policy makers and practitioners have a right to be proud of the impact of interventions such as needle and syringe programmes on HIV risk, we can be less sanguine about the ongoing high levels of HCV t[...]Périodique
I. VAN BEEK ; R. DWYER ; G. J. DORE ; K. LUO ; J. M. KALDOR | 1998FRANÇAIS : La cohorte étudiée a été recrutée parmi les patients d'un centre de prévention et traitement du VIH/Sida et autres maladies infectieuses à Sydney, qui accueille des usagers de drogues par voie injectable et des prostitués depuis 1987[...]Article : Périodique
S. BAJIS ; G. J. DORE ; B. HAJARIZADEH ; E. B. CUNNINGHAM ; L. MAHER ; J. GREBELY |Background: The burden of hepatitis C virus (HCV) infection is escalating among people who inject drugs (PWID), yet testing and treatment remains suboptimal. The aim of this systematic review was to evaluate the effectiveness of interventions to[...]Article : Périodique
J. GREBELY ; P. BRUGGMANN ; M. BACKMUND ; G. J. DORE |The majority of hepatitis C virus (HCV) occurs among people who inject drugs (PWID), and the burden of HCV-related liver disease is still increasing. HCV treatment is safe and effective among PWID, and international guidelines encourage HCV trea[...]Article : Périodique
G. ROBAEYS ; J. GREBELY ; S. MAUSS ; P. BRUGGMANN ; J. MOUSSALLI ; A. DE GOTTARDI ; T. SWAN ; A. ARAIN ; A. KAUTZ ; H. STÖVER ; H. WEDEMEYER ; M. SCHAEFER ; L. TAYLOR ; M. BACKMUND ; O. DALGARD ; M. PRINS ; G. J. DORE |In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treatment uptake among PWID remains [...]Article : Périodique
J. GREBELY ; J. BRUNEAU ; J. V. LAZARUS ; O. DALGARD ; P. BRUGGMANN ; C. TRELOAR ; M. HICKMAN ; M. HELLARD ; T. ROBERTS ; L. CROOKS ; H. MIDGARD ; S. LARNEY ; L. DEGENHARDT ; H. ALHO ; J. BYRNE ; J. F. DILLON ; J. J. FELD ; G. FOSTER ; D. GOLDBERG ; A. R. LLOYD ; J. REIMER ; G. ROBAEYS ; M. TORRENS ; N. WRIGHT ; I. MAREMMANI ; B. L. NORTON ; A. H. LITWIN ; G. J. DORE ; International Network on Hepatitis in Substance Users |Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7.5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among th[...]Nouveauté
Périodique
M. A. STOOVE ; S. M. GIFFORD ; G. J. DORE | 2005ENGLISH : More than 160,000 people are living with chronic hepatitis C virus (HCV) infection in Australia, however, rates of medical treatment are low. The aim of this study is to examine uptake and predictors of HCV-related health care servic[...]Article : Périodique
E. ASPINALL ; S. CORSON ; J. S. DOYLE ; J. GREBELY ; S. J. HUTCHINSON ; G. J. DORE ; D. J. GOLDBERG ; M. E. HELLARD |BACKGROUND: Although guidelines recommend that people who inject drugs (PWID) should not be excluded from hepatitis C (HCV) treatment, some services remain reluctant to treat PWID. The aim of this review was to investigate sustained virologic re[...]
